INDVIndivior Pharmaceuticals, Inc.

1. Oct 6, 2026As previously reported, on August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (the “Indivior”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware corporation (“Supernus”) and Artemis Merger Sub Inc., a Delaware corporation and a …Other event · Form 8-K
2. Sep 15, 2026On September 9, 2026, Indivior UK Limited ("Indivior") and Reckitt Benckiser Healthcare (UK) Limited ("RB") entered into a Deed of Variation and Termination relating to that certain Copacker Supply Agreement dated December 23, 2014, as was amended on March 29, 2019 (the "Copacker Supply Agreement")Material agreement terminated · Form 8-K
3. Aug 3, 2026Merger of Equals to Create a.Regulation FD disclosure · press release
4. Aug 3, 2026Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance.Earnings release · press release
5. Aug 3, 2026Agreement and Plan of Merger On August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (“Indivior”) and Artemis Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Indivior (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus …Material agreement entered · Form 8-K
6. May 15, 2026Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer.Director or officer change · Form 8-K
7. May 4, 2026On May 4, 2026 the Company issued a press release announcing that it had entered into an accelerated share repurchase agreement (the “ASR Agreement”) with an investment bank counterparty (the “Counterparty Bank”) to repurchase $175.0 million (the “Prepayment Amount”) of shares of the Company’s common stock, par value …Regulation FD disclosure · Form 8-K
8. Apr 30, 2026Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance.Earnings release · press release
9. Mar 17, 2026Indenture On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “Company”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “Notes”; the “Convertible Notes Offering”)Material agreement entered · Form 8-K
10. Mar 13, 2026On March 12, 2026, the Company announced the pricing of its offering of 0.625% convertible senior notes due 2031 (the “Notes”)Other event · Form 8-K
11. Mar 12, 2026On March 12, 2026, the Company announced the launch of its proposed offering of convertible senior notes due 2031 (the “Notes”)Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.